Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 7, 2017; 23(21): 3815-3824
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3815
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3815
Table 1 Frequencies of alleles and genotypes of analyzed IFNL3 (IL28B) single nucleotide polymorphism in the group of patients enrolled (n = 196) n (%)
SNP | Allele frequency | Genotype frequency |
rs4803217 (C/A) | C: 215 (54.85) | CC: 54 (27.55) |
A: 177 (45.15)1 | CA: 107 (54.59) | |
AA: 35 (17.86) | ||
rs12979860 (C/T) | C: 212 (54.08) | CC: 53 (27.04) |
T: 180 (45.92)1 | CT: 106 (54.08) | |
TT: 37 (18.88) | ||
rs8099917 (T/G) | T: 252 (64.29) | TT: 75 (38.27) |
G: 140 (35.71)1 | TG: 102 (52.04) | |
GG: 19 (9.69) | ||
rs12980275 (A/G) | A: 227 (57.91) | AA: 64 (32.65) |
G: 165 (42.09)1 | AG: 99 (50.51) | |
GG: 33 (16.84) |
Table 2 Association between IFNL3 (IL28B) single nucleotide polymorphism and sustained virological response after pegylated interferon alpha and ribavirin treatment in chronic hepatitis C patients
SNP | Allele/genotype | Response (n = 54), n (%) | Non-response (n = 126), n (%) | Response vs non-response | ORcrude (95%CI)/ORadjusted (95%CI)1 | Pcrude/Padjusted1 |
rs4803217 (C/A) | C/A | 85 (78.70)/23 (21.30) | 109 (43.25)/143 (56.75) | C/A | 4.848 (2.871-8.186) | < 0.0001a |
CC | 34 (62.96) | 14 (11.11) | CC/CA + AA | 13.6 (6.219-29.770)/8.357 (3.013-23.181) | < 0.0001a/< 0.0001a | |
CA | 17 (31.48) | 81 (64.29) | CC + CA/AA | 5.547 (1.617-19.035)/3.240 (0.849-12.367) | 0.003a/0.082 | |
AA | 3 (55.56) | 31 (24.60) | Dose of C allele | 7.588 (3.858-14.922)/4.310 (1.956-9.500) | < 0.0001a/0.0002a | |
rs12979860 (C/T) | C/T | 82 (75.93)/26 (24.07) | 108 (42.86)/144 (57.14) | C/T | 4.205 (2.533-6.980) | < 0.0001a |
CC | 32 (59.26) | 14 (11.11) | CC/CT + TT | 11.636 (5.351-25.306)/9.765 (3.407-27.990) | < 0.0001a/< 0.0001a | |
CT | 18 (33.33) | 80 (63.49) | CC + CT/TT | 4.255 (1.424-12.715)/4.413 (0.927-21.011) | 0.006a/0.059 | |
TT | 4 (7.41) | 32 (25.40) | Dose of C allele | 6.072 (3.195-11.538)/5.574 (2.345-13.246) | < 0.0001a/< 0.0001a | |
rs8099917 (T/G) | T/G | 80 (74.07)/28 (25.93) | 149 (59.13)/103 (40.87) | T/G | 1.975 (1.2-3.251) | 0.007a |
TT | 29 (53.70) | 39 (30.95) | TT/TG + GG | 2.588 (1.344-4.981)/2.097 (0.844-5.210) | 0.004a/0.107 | |
TG | 22 (40.74) | 71 (56.35) | TT + TG/GG | 2.473 (0.690-8.867)/2.397 (0.482-11.926) | 0.153/0.280 | |
GG | 3 (5.56) | 16 (12.70) | Dose of T allele | 2.190 (1.266-3.788)/1.869 (0.911-3.837) | 0.0048a/0.0845 | |
rs12980275 (A/G) | A/G | 85 (78.70)/23 (21.30) | 120 (47.62)/132 (52.38) | A/G | 4.065 (2.410-6.857) | < 0.0001a |
AA | 35 (64.81) | 23 (18.25) | AA/AG + GG | 8.249 (4.021-16.923)/5.225 (1.999-13.658) | < 0.0001a/0.001a | |
AG | 15 (27.78) | 74 (58.73) | AA + AG/GG | 3.737 (1.244-11.223)/4.075 (0.848-19.589) | 0.013a/0.076 | |
GG | 4 (7.41) | 29 (23.02) | Dose of A allele | 4.705 (2.591-8.542)/3.596 (1.659-7.791) | < 0.0001a/0.001a |
Table 3 Multivariate analysis of factors associated with outcome of chronic hepatitis C treatment with pegylated interferon alpha and ribavirin
Variable | OR (95%CI) | P value |
Response (SVR)1 | ||
rs4803217 (C/A) | 4.979 (1.344-18.444) | 0.016a |
rs12979860 (C/T) | 1.499 (0.446-5.042) | 0.510 |
rs8099917 (T/G) | 0.594 (0.247-1.429) | 0.242 |
rs12980275 (A/G) | 1.658 (0.598-4.594) | 0.328 |
Stage of fibrosis | 3.278 (1.108-9.698) | 0.031a |
Relapse2 | ||
rs4803217 (C/A) | 0.134 (0.023-0.789) | 0.024a |
rs12979860 (C/T) | 2.381 (0.444-12.773) | 0.303 |
rs12980275 (A/G) | 1.046 (0.369-2.961) | 0.932 |
Table 4 Association of IFNL3 (IL28B) rs4803217 and rs8099917 combined genotypes with response to pegylated interferon alpha and ribavirin treatment
Genotypes/combined genotypes | SVR (n = 54), n | Non-response (n = 126), n | OR (95%CI) | P value |
rs4803217CC/rs8099917TT | 22 | 13 | 0.697 (0.276-1.759) | 0.442 |
rs4803217CC/rs8099917TG | 12 | 1 | 4.941 (0.586-41.699) | 0.156 |
rs4803217CC1 | 34 | 14 | Ref. | - |
rs4803217CA/rs8099917TT | 5 | 9 | 2.813 (0.832-9.504) | 0.136 |
rs4803217CA/rs8099917TG | 9 | 71 | 0.641 (0.267-1.542) | 0.388 |
rs4803217CA/rs8099917GG | 2 | 1 | 10.125 (0.865-118.471) | 0.083 |
rs4803217CA | 16 | 81 | Ref. | - |
rs4803217AA/rs8099917TT | 1 | 2 | 5.167 (0.355-75.138) | 0.298 |
rs4803217AA/rs8099917TG | 1 | 14 | 0.738 (0.070-7.736) | 1.000 |
rs4803217AA/rs8099917GG | 1 | 15 | 0.689 (0.066-7.192) | 1.000 |
rs4803217AA | 3 | 31 | Ref. | - |
Table 5 Association between IFNL3 (IL28B) gene single nucleotide polymorphism and relapse after pegylated interferon alpha and ribavirin treatment in chronic hepatitis C patients
SNP | Allele/genotype | Relapse (n = 39), n (%) | Non-relapse (n = 38), n (%) | Relapse vs non-relapse | OR (95%CI) | P value |
rs4803217 (C/A) | C/A | 38 (48.72)/40 (51.28) | 56 (73.68)/20 (26.32) | C vs A | 0.339 (0.173-0.667) | 0.001a |
CC | 7 (17.95) | 21 (55.26) | CC vs CA + AA | 0.177 (0.063-0.500) | 0.0007a | |
CA | 24 (61.54) | 14 (36.84) | CC + CA vs AA | 0.332 (0.081-1.364) | 0.113 | |
TT | 8 (20.51) | 3 (7.89) | Dose of C allele | 0.296 (0.134-0.653) | 0.002a | |
rs12979860 (C/T) | C/T | 40 (51.28)/38 (48.72) | 52 (68.42)/24 (31.58) | C vs T | 0.486 (0.252-0.937) | 0.030a |
CC | 8 (20.51) | 18 (47.37) | CC vs CT + TT | 0.287 (0.105-0.783) | 0.013a | |
CT | 24 (61.54) | 16 (42.11) | CC + CT vs TT | 0.538 (0.143-2.013) | 0.351 | |
TT | 7 (17.95) | 4 (10.53) | Dose of C allele | 0.442 (0.211-0.925) | 0.028a | |
rs8099917 (T/G) | T/G | 56 (71.79)/22 (28.21) | 52 (68.42)/24 (31.58) | T vs G | 1.175 (0.589-2.344) | 0.647 |
TT | 21 (53.85) | 17 (44.74) | TT vs TG + GG | 1.304 (0.526-3.233) | 0.566 | |
TG | 14 (35.90) | 18 (47.37) | TT + TG vs GG | 0.750 (0.156-3.560) | 1.000 | |
GG | 4 (10.26) | 3 (7.89) | Dose of T allele | 1.174 (0.582-2.365) | 0.649 | |
rs12980275 (A/G) | A/G | 45 (57.69)/33 (42.31) | 56 (73.68)/20 (26.32) | A vs G | 0.487 (0.247-0.961) | 0.037a |
AA | 12 (30.77) | 22 (57.89) | AA vs AG + GG | 0.323 (0.127-0.825) | 0.017a | |
AG | 21 (53.85) | 12 (31.58) | AA + AG vs GG | 0.647 (0.167-2.503) | 0.737 | |
GG | 6 (15.38) | 4 (10.53) | Dose of A allele | 0.495 (0.245-0.998) | 0.046a |
- Citation: Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol 2017; 23(21): 3815-3824
- URL: https://www.wjgnet.com/1007-9327/full/v23/i21/3815.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i21.3815